References
- Sanders CC, Sanders WE. 13-lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 824–39.
- McGowan JE. Resistance in nonfermenting Gram-nega-tive bacteria: multidrug resistance to the maximum. Am J Med 2006; 119: 29–36.
- Rubinstein E, Vaughan D. Tigecycline: a novel glyclycyc-line. Drugs 2005; 56: 1317–36.
- Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470–80.
- Frampton JE, Curran MP. Tigecycline. Drugs 2005 65 ;2623–35.
- Kasbekar N. Tigecycline: a new glyclycline antimicrobial agent. Am J Health Syst Pharm 2006; 63: 1235–43.
- Peterson LR. Antimicrobial activity and pharmacokinet-ics/pharmacodynamics of the novel glycylcycline, tigecycline. Diagn Microbiol Infect Dis 2005; 52: 163–4.
- Muralidharan G, Micalizzi, M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220–229.
- Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis, 2005; 41: 333–340.
- Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bac-teremias. J Chemother 2007; 19: 232–233.